Navigation Links
CTI Announces Data Presentations at the 55th American Society of Hematology Annual Meeting
Date:11/7/2013

ubject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities.  Such statements include, but are not limited to, statements regarding CTI's expectations with respect to the development of CTI and its product and product candidate portfolio, the expected commencement of the PERSIST-2 clinical trial in the fourth quarter of 2013 and the expected efficacy and potential benefits of pacritinib (including that pacritinib may offer an advantage over other JAK inhibitors through effective treatment of symptoms while having less treatment-emergent thrombocytopenia and anemia than has been seen in currently approved and in-development JAK inhibitors).  Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI cannot predict or guarantee the outcome of preclinical and clinical studies, that the second Phase 3 clinical trial of pacritinib will not occur as planned, that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities, that CTI may experience delays in the commencement of preclinical and clinical studies, risks related to the costs of developing pacritinib and CTI's other product candidates, and other risks, including, without limitation, competitive factors, technological developments, that CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI may not achieve previously announced goals and objectives as or when projected, that C
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ambit Biosciences Announces Third Quarter 2013 Operating Results
2. Spherix Announces the Closing of Private Placement of $2,235,000
3. Intelligent Implant Systems Announces 510(k) Clearance of the Marauder Cervical-Thoracic Spinal System
4. karmadata Announces Launch Of App Gallery And The Indicate Investigators App
5. Spherix Announces Additions to Technology Advisory Board in Areas of Licensing and Litigation Support
6. InterMune Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock
7. AVS announces its major award winners of 2013
8. Metabolix Announces Third Quarter 2013 Financial Results
9. Discovery Labs Announces Completion of $50 Million Public Offering
10. Life Technologies Announces Third Quarter 2013 Results
11. Colby Pharmaceutical Company Announces Dramatic Results: Novel Technology Increases Influenza Vaccine Protection for Elderly Rhesus Monkeys
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... December 19, 2014 Charm Sciences is ... for the Detection of Aflatoxin M1 in raw commingled ... independent third party validation. The peer reviewed report of ... the Institute for Agricultural and Fisheries Research (ILVO-T&V) has ... , Aflatoxin B1, the most toxic aflatoxin and a ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
Breaking Biology Technology:Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... - Vasogen Inc.,(NASDAQ: VSGN ; TSX:VAS) today reported the ... August 31, 2008. All dollar amounts referenced,herein are in ... 2008, our cash and cash equivalents totaled $9.8 million,compared ... net loss for the third quarter of 2008 was ...
... 15 Quincy Bioscience (Madison, WI),announces that ... of the jellyfish protein apoaequorin, has displayed ... subjects tested. The Prevagen,Memory Study included 56 ... mg/day). The findings suggest that supplementation with,apoaequorin, ...
... 08/07 ... millions sales change millions sales change, ... 16 Other EU countries (2) 7.1 24 17 8.6 ... 24 1.8 5 18, SLIT ...
Cached Biology Technology:Vasogen Announces Third Quarter 2008 Results 2Vasogen Announces Third Quarter 2008 Results 3Vasogen Announces Third Quarter 2008 Results 4Vasogen Announces Third Quarter 2008 Results 5Vasogen Announces Third Quarter 2008 Results 6Vasogen Announces Third Quarter 2008 Results 7Vasogen Announces Third Quarter 2008 Results 8Vasogen Announces Third Quarter 2008 Results 9Vasogen Announces Third Quarter 2008 Results 10Jellyfish Protein Shows Potential to Help With Memory 2Jellyfish Protein Shows Potential to Help With Memory 3Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14% 2Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14% 3
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... in the rugged Marquesas Islands (French Polynesia) have increased the ... research and collecting in conjunction with the Vascular Flora ... Polynesie franaise projects have yielded 62 new species of ... 360, of which 18 are newly described and illustrated in ...
... available in German . They live their lives upside ... position, sloths spend most of their lives hanging in trees upside ... Very slowly. But why are sloths so ,lazy,? And how has ... in the course of evolution? Zoologists of the Friedrich Schiller University ...
... to be genes that, when mutated, change healthy cells into ... of the University of Southern California (USC) have proven that ... paving the way to a safer and more practical approach ... cell therapy. "The reality may be more complicated than ...
Cached Biology News:Marquesas Islands in French Polynesia yield 18 new species of rare ferns and flowering plants 2The decoding of slowness 2USC research: Cancer cells and stem cells share same origin 2
... Partek Genomics Solution is a comprehensive ... data visualization specifically designed to reliably ... for high-dimensional genomic studies containing thousands ... fast, memory efficient and will analyze ...
Kit contains: Bio-Rad Amplification Reagent, 2x Amplification Diluent, Streptavidin-HRP, Blocking Reagent, and Phosphate Buffered Saline....
These macrocarriers are for the biolistic PDS-1000 He and Hepta systems. Supplied as 500 macrocarriers....
Intestinal Epithelium Differentiation Environment...
Biology Products: